LEXARIA BIOSCIENCE CORP. Research and Development Expense
LEXARIA BIOSCIENCE CORP. (LEXX) reported Research and Development Expense of $970.83 thousand for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. research and development expense for the quarter ending 2026-05-31 was $970.83K, a 64.27% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. research and development expense for the quarter ending 2026-02-28 was $475.39K, a 71.80% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. research and development expense for the quarter ending 2025-11-30 was $671.34K, a 65.63% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. research and development expense for the quarter ending 2025-08-31 was $1.88M, a 94.59% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. research and development expense for fiscal 2025 was $8.24M, a 249.02% increase from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. research and development expense for fiscal 2024 was $2.36M, a 35.62% decline from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. research and development expense for fiscal 2023 was $3.67M, a 98.99% increase from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. research and development expense for fiscal 2022 was $1.84M, a 45.91% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-05-31 | $970.83K 10-Q · filed 2026-07-13 | $1.45M derived: sum of 2 quarters · filed 2026-07-13 | $2.12M 10-Q · filed 2026-07-13 | $4.00M derived: sum of 4 quarters · filed 2026-07-13 |
| 2026-02-28 | $475.39K 10-Q · filed 2026-04-13 | $1.15M 10-Q · filed 2026-04-13 | $3.03M derived: sum of 3 quarters · filed 2026-04-13 | $5.75M derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-11-30 | $671.34K 10-Q · filed 2026-01-13 | $2.55M derived: sum of 2 quarters · filed 2026-01-13 | $5.27M derived: sum of 3 quarters · filed 2026-07-13 | $6.96M derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-08-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $4.60M derived: sum of 2 quarters · filed 2026-07-13 | $6.29M derived: sum of 3 quarters · filed 2026-07-13 | $8.24M 10-K · filed 2025-11-28 |
| 2025-05-31 | $2.72M 10-Q · filed 2026-07-13 | $4.40M derived: sum of 2 quarters · filed 2026-07-13 | $6.36M 10-Q · filed 2026-07-13 | $7.32M derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-02-28 | $1.69M 10-Q · filed 2026-04-13 | $3.64M 10-Q · filed 2026-04-13 | $4.61M derived: sum of 3 quarters · filed 2026-04-13 | $5.18M derived: sum of 4 quarters · filed 2026-04-13 |
| 2024-11-30 | $1.95M 10-Q · filed 2026-01-13 | $2.92M derived: sum of 2 quarters · filed 2026-01-13 | $3.49M derived: sum of 3 quarters · filed 2026-01-13 | $3.74M derived: sum of 4 quarters · filed 2026-01-13 |
| 2024-08-31 | $967.21K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | $1.54M derived: sum of 2 quarters · filed 2025-11-28 | $1.79M derived: sum of 3 quarters · filed 2025-11-28 | $2.36M 10-K · filed 2025-11-28 |
| 2024-05-31 | $573.09K 10-Q · filed 2025-07-14 | $818.87K derived: sum of 2 quarters · filed 2025-07-14 | $1.39M 10-Q · filed 2025-07-14 | $1.89M derived: sum of 4 quarters · filed 2025-07-14 |
| 2024-02-29 | $245.78K 10-Q · filed 2025-04-14 | $820.27K 10-Q · filed 2025-04-14 | $1.32M derived: sum of 3 quarters · filed 2025-04-14 | $2.96M derived: sum of 4 quarters · filed 2025-04-14 |
| 2023-11-30 | $574.49K 10-Q · filed 2025-01-10 | $1.07M derived: sum of 2 quarters · filed 2025-01-10 | $2.72M derived: sum of 3 quarters · filed 2025-01-10 | $3.41M derived: sum of 4 quarters · filed 2025-01-10 |
| 2023-08-31 | $500.41K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $2.14M derived: sum of 2 quarters · filed 2024-11-26 | $2.84M derived: sum of 3 quarters · filed 2024-11-26 | $3.67M 10-K · filed 2024-11-26 |
| 2023-05-31 | $1.64M 10-Q · filed 2024-07-12 | $2.34M derived: sum of 2 quarters · filed 2024-07-12 | $3.17M 10-Q · filed 2024-07-12 | $3.52M derived: sum of 4 quarters · filed 2024-07-12 |
| 2023-02-28 | $696.18K 10-Q · filed 2024-04-09 | $1.53M 10-Q · filed 2024-04-09 | $1.88M derived: sum of 3 quarters · filed 2024-04-09 | $2.63M derived: sum of 4 quarters · filed 2024-04-09 |
| 2022-11-30 | $829.49K 10-Q · filed 2024-01-12 | $1.19M derived: sum of 2 quarters · filed 2024-01-12 | $1.94M derived: sum of 3 quarters · filed 2024-01-12 | $2.21M derived: sum of 4 quarters · filed 2024-01-12 |
| 2022-08-31 | $356.19K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | $1.11M derived: sum of 2 quarters · filed 2023-11-20 | $1.38M derived: sum of 3 quarters · filed 2023-11-20 | $1.84M 10-K · filed 2023-11-20 |
| 2022-05-31 | $752.10K 10-Q · filed 2023-07-14 | $1.03M derived: sum of 2 quarters · filed 2023-07-14 | $1.49M 10-Q · filed 2023-07-14 | $1.93M derived: sum of 4 quarters · filed 2023-07-14 |
| 2022-02-28 | $275.69K 10-Q · filed 2023-04-14 | $734.39K 10-Q · filed 2023-04-14 | $1.17M derived: sum of 3 quarters · filed 2023-04-14 | $1.63M derived: sum of 4 quarters · filed 2023-04-14 |
| 2021-11-30 | $458.71K 10-Q/A · filed 2023-01-18 | $898.50K derived: sum of 2 quarters · filed 2023-01-18 | $1.35M derived: sum of 3 quarters · filed 2023-01-18 | $1.53M derived: sum of 4 quarters · filed 2023-01-18 |
| 2021-08-31 | $439.79K derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $894.24K derived: sum of 2 quarters · filed 2022-11-28 | $1.07M derived: sum of 3 quarters · filed 2022-11-28 | $1.26M 10-K · filed 2022-11-28 |
| 2021-05-31 | $454.44K 10-Q · filed 2022-07-14 | $630.84K derived: sum of 2 quarters · filed 2022-07-14 | $823.10K 10-Q · filed 2022-07-14 | $891.60K derived: sum of 4 quarters · filed 2022-07-14 |
| 2021-02-28 | $176.40K 10-Q · filed 2022-04-11 | $368.66K 10-Q · filed 2022-04-11 | $437.16K derived: sum of 3 quarters · filed 2022-04-11 | $461.71K derived: sum of 4 quarters · filed 2022-04-11 |
| 2020-11-30 | $192.26K 10-Q · filed 2022-01-14 | $260.76K derived: sum of 2 quarters · filed 2022-01-14 | $285.31K derived: sum of 3 quarters · filed 2022-01-14 | $471.87K derived: sum of 4 quarters · filed 2022-01-14 |
| 2020-08-31 | $68.50K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | $93.05K derived: sum of 2 quarters · filed 2021-11-29 | $279.61K derived: sum of 3 quarters · filed 2021-11-29 | $387.07K 10-K · filed 2021-11-29 |
| 2020-05-31 | $24.56K 10-Q · filed 2021-07-15 | $211.11K derived: sum of 2 quarters · filed 2021-07-15 | $318.58K 10-Q · filed 2021-07-15 | $480.22K derived: sum of 4 quarters · filed 2021-07-15 |
| 2020-02-29 | $186.56K 10-Q · filed 2021-04-14 | $294.02K 10-Q · filed 2021-04-14 | $455.66K derived: sum of 3 quarters · filed 2021-04-14 | $686.69K derived: sum of 4 quarters · filed 2021-04-14 |
| 2019-11-30 | $107.46K 10-Q · filed 2021-01-14 | $269.10K derived: sum of 2 quarters · filed 2021-01-14 | $500.14K derived: sum of 3 quarters · filed 2021-01-14 | $566.22K derived: sum of 4 quarters · filed 2021-01-14 |
| 2019-08-31 | $161.64K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-15 | $392.67K derived: sum of 2 quarters · filed 2020-10-15 | $458.76K derived: sum of 3 quarters · filed 2020-10-15 | $555.73K 10-K · filed 2020-10-15 |
| 2019-05-31 | $231.03K 10-Q · filed 2020-06-29 | $297.12K derived: sum of 2 quarters · filed 2020-06-29 | $394.09K 10-Q · filed 2020-06-29 | $607.73K derived: sum of 4 quarters · filed 2020-06-29 |
| 2019-02-28 | $66.08K 10-Q · filed 2020-04-03 | $163.06K 10-Q · filed 2020-04-03 | $376.70K derived: sum of 3 quarters · filed 2020-04-03 | $469.77K derived: sum of 4 quarters · filed 2020-04-03 |
| 2018-11-30 | $96.97K 10-Q · filed 2020-01-09 | $310.62K derived: sum of 2 quarters · filed 2020-01-09 | $403.68K derived: sum of 3 quarters · filed 2020-01-09 | $479.44K derived: sum of 4 quarters · filed 2020-01-09 |
| 2018-08-31 | $213.64K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-14 | $306.71K derived: sum of 2 quarters · filed 2019-11-14 | $382.47K derived: sum of 3 quarters · filed 2019-11-14 | $492.86K 10-K · filed 2019-11-14 |
| 2018-05-31 | $93.07K 10-Q · filed 2019-07-08 | $168.83K derived: sum of 2 quarters · filed 2019-07-08 | $279.22K 10-Q · filed 2019-07-08 | $310.13K derived: sum of 4 quarters · filed 2019-07-08 |
| 2018-02-28 | $75.76K 10-Q · filed 2019-04-15 | $186.15K 10-Q · filed 2019-04-15 | $217.06K derived: sum of 3 quarters · filed 2019-04-15 | $225.30K derived: sum of 4 quarters · filed 2019-04-15 |
| 2017-11-30 | $110.39K 10-Q · filed 2019-01-11 | $141.30K derived: sum of 2 quarters · filed 2019-01-11 | $149.54K derived: sum of 3 quarters · filed 2019-01-11 | $157.32K derived: sum of 4 quarters · filed 2019-01-11 |
| 2017-08-31 | $30.91K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-14 | $39.15K derived: sum of 2 quarters · filed 2018-11-14 | $46.92K derived: sum of 3 quarters · filed 2018-11-14 | $54.19K 10-K · filed 2018-11-14 |
| 2017-05-31 | $8.24K 10-Q · filed 2018-07-13 | $16.02K derived: sum of 2 quarters · filed 2018-07-13 | $23.28K 10-Q · filed 2018-07-13 | $23.32K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-02-28 | $7.78K 10-Q · filed 2018-04-12 | $15.04K 10-Q · filed 2018-04-12 | $15.08K derived: sum of 3 quarters · filed 2018-11-14 | $15.23K derived: sum of 4 quarters · filed 2018-11-14 |
| 2016-11-30 | $7.26K 10-Q · filed 2018-01-12 | $7.30K derived: sum of 2 quarters · filed 2018-11-14 | $7.46K derived: sum of 3 quarters · filed 2018-11-14 | $14.31K derived: sum of 4 quarters · filed 2018-11-14 |
| 2016-08-31 | $37.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-14 | $195.00 derived: sum of 2 quarters · filed 2018-11-14 | $7.05K derived: sum of 3 quarters · filed 2018-11-14 | $9.02K 10-K · filed 2018-11-14 |
| 2016-05-31 | $158.00 10-Q · filed 2017-07-14 | $7.01K derived: sum of 2 quarters · filed 2017-07-14 | $8.99K 10-Q · filed 2017-07-14 | $107.07K derived: sum of 4 quarters · filed 2017-07-14 |
| 2016-02-29 | $6.85K 10-Q · filed 2017-04-14 | $8.83K 10-Q · filed 2017-04-14 | $106.91K derived: sum of 3 quarters · filed 2017-04-14 | $107.02K derived: sum of 4 quarters · filed 2017-04-14 |
| 2015-11-30 | $1.98K 10-Q · filed 2017-01-13 | $100.06K derived: sum of 2 quarters · filed 2017-01-13 | $100.17K derived: sum of 3 quarters · filed 2017-01-13 | $100.41K derived: sum of 4 quarters · filed 2017-01-13 |
| 2015-08-31 | $98.08K derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-29 | $98.19K derived: sum of 2 quarters · filed 2016-11-29 | $98.43K derived: sum of 3 quarters · filed 2016-11-29 | $146.47K 10-K · filed 2016-11-29 |
| 2015-05-31 | $107.00 10-Q · filed 2016-07-13 | $347.00 derived: sum of 2 quarters · filed 2016-07-13 | $48.39K 10-Q · filed 2016-07-13 | $48.39K derived: sum of 4 quarters · filed 2016-07-13 |
| 2015-02-28 | $240.00 10-Q · filed 2016-04-13 | $48.28K 10-Q · filed 2016-04-13 | $48.28K derived: sum of 3 quarters · filed 2016-04-13 | $48.28K derived: sum of 4 quarters · filed 2016-04-13 |
| 2014-11-30 | $48.04K 10-Q · filed 2016-01-08 | $48.04K derived: sum of 2 quarters · filed 2016-01-08 | $48.04K derived: sum of 3 quarters · filed 2016-01-08 | $48.04K derived: sum of 4 quarters · filed 2016-01-08 |
| 2014-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-11-27 | $0.00 derived: sum of 2 quarters · filed 2015-11-27 | $0.00 derived: sum of 3 quarters · filed 2015-11-27 | $0.00 10-K · filed 2015-11-27 |
| 2014-05-31 | $0.00 10-Q · filed 2015-07-14 | $0.00 derived: sum of 2 quarters · filed 2015-07-14 | $0.00 10-Q · filed 2015-07-14 | |
| 2014-02-28 | $0.00 10-Q · filed 2015-04-14 | $0.00 10-Q · filed 2015-04-14 | ||
| 2013-11-30 | $0.00 10-Q · filed 2015-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |